VERAXA Biotech (NASDAQ: VRXA) announced that shareholders overwhelmingly approved all proposals presented at its Extraordinary General Meeting, with more than 99.94% of votes cast in favor and 72.20% of the company's outstanding share capital represented. The approved measures include the introduction of conditional share capital for shareholder options and warrants, implementation of a capital band through Dec. 31, 2030, and an increase in the maximum size of the board of directors from five to seven members.
The company said the enhanced corporate and financing framework is intended to support its long-term growth strategy by providing greater flexibility for potential acquisitions, strategic collaborations, investment projects, capital markets activities, and continued development of its BiTAC(R) technology platform and oncology pipeline. Management said the vote reflects strong shareholder support for VERAXA's strategy of advancing antibody-based cancer therapeutics while pursuing long-term value creation.
This approval is significant as it empowers VERAXA to pursue a more aggressive growth agenda. The capital band allows the board to issue new shares within a defined range without further shareholder approval, streamlining future financing rounds. The increased board size can bring in additional expertise, particularly in areas like clinical development and business development. These changes position VERAXA to capitalize on its BiTAC platform and advance its pipeline of antibody-based cancer therapies.
VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development. The company was founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), a world-renowned institution.
For more details, the full press release is available at https://ibn.fm/qfL87. The latest news and updates relating to VRXA can be found in the company's newsroom at https://ibn.fm/VRXA.
